• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Sieger Markus claimed ownership of 155,182 units of Class B Common Stock (SEC Form 3)

    4/2/25 10:56:32 AM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Sieger Markus

    (Last) (First) (Middle)
    C/O RAFAEL HOLDINGS, INC.
    520 BROAD STREET

    (Street)
    NEWARK NJ 07102

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/25/2025
    3. Issuer Name and Ticker or Trading Symbol
    Rafael Holdings, Inc. [ RFL ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Class B Common Stock, par value $.01 per share 155,182(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) 08/27/2021 08/27/2031 Class B Common Stock 2,362(1) $21.16 D
    Stock Option (right to buy) 03/07/2023 03/07/2033 Class B Common Stock 1,181(1) $3.63 D
    Stock Option (right to buy) 06/03/2024 06/03/2034 Class B Common Stock 5,485(1) $3.63 D
    Class B Common Stock Warrant (Right to Buy) 04/23/2018 04/23/2025 Class B Common Stock 352(1) $70.93 D
    Class B Common Stock Warrant (Right to Buy) 12/21/2018 12/21/2025 Class B Common Stock 352(1) $184.41 D
    Class B Common Stock Warrant (Right to Buy) 08/27/2020 08/27/2027 Class B Common Stock 2,644(1) $42.56 D
    Class B Common Stock Warrant (Right to Buy) 10/20/2023 10/20/2027 Class B Common Stock 23,217(1) $2.7 D
    Explanation of Responses:
    1. The shares, options and warrants set forth in this Form 3 were all received in exchange for shares, options and warrants, respectively, of Cyclo Therapeutics, Inc. ("Cyclo") common stock and upon conversion of options and warrants to purchase shares of Cyclo common stock in connection with the business combination between the Issuer and Cyclo on March 25, 2025.
    /s/ Markus Sieger 04/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RFL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    SEC Filings

    See more
    • Rafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      6/18/25 7:13:55 AM ET
      $RFL
      Real Estate
      Finance
    • SEC Form 10-Q filed by Rafael Holdings Inc.

      10-Q - Rafael Holdings, Inc. (0001713863) (Filer)

      6/11/25 7:53:42 AM ET
      $RFL
      Real Estate
      Finance
    • Rafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Rafael Holdings, Inc. (0001713863) (Filer)

      6/11/25 7:19:07 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

      Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

      8/22/24 6:50:00 AM ET
      $CYTH
      $RFL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Real Estate
      Finance
    • Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

      CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. ("Cornerstone" or the "Company"), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the appointment of Jason Locasale, Ph.D., as a member of the Company's Scientific Advisory Board. Dr. Locasale is a highly respected scholar and brings to Cornerstone deep expertise in cancer metabolism, metabolomics, nutrition and the metabolic interface of epigenetics. "Dr. Locasale is an internationally recognized leader in the use of metabolomics approaches to study cancer biology and metabolism," said Sanjeev Luther, President & CEO at Cornerstone Pharmaceutical

      7/6/22 8:00:00 AM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec Chairman, CEO & President Jonas Howard S was granted 118,596 units of Class B Common Stock, increasing direct ownership by 75% to 277,612 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/17/25 2:22:37 PM ET
      $RFL
      Real Estate
      Finance
    • Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/9/25 5:19:19 PM ET
      $RFL
      Real Estate
      Finance
    • Chief Financial Officer Polinsky David exercised 76,882 in-the-money units of Class B Common Stock at a strike of $1.28, increasing direct ownership by 40% to 270,422 units (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      5/30/25 1:56:44 PM ET
      $RFL
      Real Estate
      Finance

    $RFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

      4 - Rafael Holdings, Inc. (0001713863) (Issuer)

      6/9/25 5:19:19 PM ET
      $RFL
      Real Estate
      Finance